Actinogen Medical (ASX:ACW) has been suspended from quotation on the ASX effective from the open of trading on Tuesday, 17 November 2026, at the company's own request, pending a material announcement regarding additional clinical trial results data received that day for its XanaMIA phase 2b/3 Alzheimer's disease trial.
Key Points
- Actinogen Medical requested a voluntary suspension of its quoted securities from the open of trading on 17 November 2026 under ASX Listing Rule 17.2.
- The suspension is pending the release of topline clinical trial results for the XanaMIA phase 2b/3 Alzheimer's disease trial.
- Additional clinical trial results data for the XanaMIA phase 2b/3 trial were received by the company on 17 November 2026.
- The voluntary suspension is to remain in place until the earlier of the company making an announcement on the trial results or the commencement of trading on Thursday, 19 November 2026.
Voluntary Suspension Request and Conditions
The suspension was issued by ASX Supervision immediately upon request from Actinogen Medical, in accordance with Listing Rule 17.2. The securities will remain suspended until the earlier of the end of the period stated in the company's voluntary suspension request or the release of the relevant announcement to the market. The company stated it is not aware of any reason why the voluntary suspension should not be granted, and is not aware of any other information necessary to inform the market about the suspension. The request was signed by Company Secretary Peter Webse.
XanaMIA Phase 2b/3 Alzheimer's Disease Trial
The XanaMIA phase 2b/3 trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial enrolling 247 patients with mild to moderate Alzheimer's disease. Patients receive Xanamem 10 mg or placebo once daily. The primary endpoint is the CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial has been conducted in Australia and the United States, is closed to participant recruitment, and has passed an independent Data Monitoring Committee safety and efficacy futility review. Final topline results were expected in November 2026, according to the filing.
Anticipated Announcement Timeline
Actinogen Medical disclosed that the voluntary suspension is to remain in place until the earlier of the company making an announcement in relation to the clinical trial results of the XanaMIA phase 2b/3 trial and the commencement of trading on Thursday, 19 November 2026. The company stated the suspension was requested pending completion of further analyses of additional clinical trial results data received on 17 November 2026. The announcement was authorised by the Disclosure Committee of Actinogen Medical Limited.




Please wait processing your request...